- Home
- SCNI vs BDRX Comparison
SCNI vs BDRX Comparison
Compare SCNI & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCNI | BDRX |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 4.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SCNI | BDRX |
|---|---|---|
| Price | $0.71 | $2.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 59.7K | ★ 2.8M |
| Earning Date | 03-27-2026 | 09-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $1,147,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.67 | ★ N/A |
| Revenue Growth | ★ 303.87 | N/A |
| 52 Week Low | $0.70 | $2.55 |
| 52 Week High | $6.18 | $92.00 |
Technical Indicators
Market Signals| Indicator | SCNI | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 29.41 | 38.49 |
| Support Level | $0.70 | $4.55 |
| Resistance Level | $0.80 | $7.22 |
| Average True Range (ATR) | 0.09 | 1.31 |
| MACD | -0.03 | -0.28 |
| Stochastic Oscillator | 3.08 | 0.00 |
Price Performance
Historical ComparisonAbout SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.